Avatrombopag is a thrombopoietin receptor agonist used to treat chronic liver disease and immune thrombocytopenia. The following introduces its contraindications and main adverse reactions.

I. Contraindications and Overall Safety

1. Contraindications

This product has no clear contraindications.

Patients allergic to avatrombopag or any excipient should avoid use.

2. Overall Safety

This product is a thrombopoietin receptor agonist, and the main risk is thrombotic and thromboembolic complications.

Platelet counts should be monitored during treatment to avoid excessive elevation.

It should not be used in an attempt to normalize platelet counts.

3. Special Risk Populations

Patients with risk factors for thromboembolism (such as hereditary thrombophilia or antiphospholipid syndrome) should use it with caution.

Patients with a history of thrombosis should inform their doctor, who will assess whether the medication is suitable.

II. Main Adverse Reactions

1. Thrombosis and Thromboembolism

Portal vein thrombosis has been reported in patients with chronic liver disease.

Arterial or venous thrombotic events may occur in patients with immune thrombocytopenia.

If symptoms such as leg swelling and pain, shortness of breath, chest pain, or abdominal pain occur, seek medical attention immediately.

2. Common Reactions in Patients with Chronic Liver Disease

Fever, abdominal pain, nausea, headache, fatigue, and peripheral edema.

These reactions are mostly mild to moderate but still require attention.

3. Common Reactions in Adults with Immune Thrombocytopenia

Headache, fatigue, bruising, epistaxis, and upper respiratory tract infection.

Arthralgia, gingival bleeding, petechiae, and nasopharyngitis are also relatively common.

4. Common Reactions in Children with Immune Thrombocytopenia

Viral infection, nasopharyngitis, cough, fever, and oropharyngeal pain.

Most reactions can be relieved with treatment adjustment.

5. Other Reactions Requiring Attention

Allergic reactions: including pruritus, rash, facial swelling, and tongue swelling.

If severe allergic symptoms occur, stop the medication immediately and seek medical attention.

III. Medication Monitoring and Patient Precautions

1. Platelet Monitoring

Monitor platelet counts regularly during treatment and adjust the dose to maintain the target level.

Platelet counts still need to be monitored for at least 4 weeks after discontinuation.

2. Drug Interactions

Dose adjustment may be required when used with dual inhibitors or inducers of CYP2C9 and CYP3A4.

Patients should inform their doctor of all medications being used, including over-the-counter drugs and supplements.

3. Use in Special Populations

Use in pregnant women may cause fetal harm, and the potential risk should be explained.

Breastfeeding women should not breastfeed during treatment and for at least 2 weeks after the last dose.

For pediatric use, an appropriate dosage form should be selected according to age, and the dose should be adjusted according to medical advice.

Elderly patients do not need dose adjustment based on age alone, but individualized monitoring is required.

4. Key Points for Patient Education

Take the medication strictly as prescribed, with food.

Tablets and granules are not directly interchangeable on a milligram-to-milligram basis.

For granules, open the capsule, mix the granules into soft food or liquid, and take immediately; do not swallow the capsule whole.

If a dose is missed, take it as soon as possible; do not take double the dose at one time.

Seek medical attention immediately if symptoms of thrombosis or severe allergic reactions occur.